Don't want ads? Subscribe or login now.

Fed. Circ. OKs Boston Drug Developer's Patent Win

By Andrew Karpan · March 11, 2024, 8:31 PM EDT

A Boston-area biotech developer that has yet to bring a product to market persuaded the Federal Circuit on Monday to affirm a finding by an administrative patent board last year that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc.

Case Number

22-2232

Court

Appellate - Federal Circuit

Nature of Suit

-

Date Filed

September 21, 2022

Recent Articles By Andrew

April 30, 2025
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive
April 29, 2025
Fed. Circ. Backs TM Denial Of Dark Green Gloves As Generic
April 25, 2025
Judge Says FDA Can Take Ozempic Off Shortage List
March 28, 2025
Doctor's Counterclaims Cut In 'Groq' TM Feud With Chipmaker
March 21, 2025
Novartis Urges Court To Make FDA Block Entresto Generic
March 18, 2025
ITC To Review Whether Tourniquet Importers Are Ignoring Ban
March 17, 2025
New Bills Target 'Patent Thickets' And 'Product Hopping'
February 24, 2025
Patent Eligibility Appeals 'Will Not Go Away,' Justices Told
February 12, 2025
Labcorp Can't Score New Trial After $384M Patent Loss
February 06, 2025
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row